All In Biotech

Drug Trial Radar · NCT02896101

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (Pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD).

Last checked: Nov 19, 2026Latest source record: Jul 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 755 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

755

Actual

Start

Aug 2016

Primary completion

Jun 2017

Study completion Jun 2017

Sponsor

Sponsor type
Industry
First posted
Sep 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • Pimecrolimus Cream, 1%Drug

  • Elidel® (pimecrolimus) CreamDrug

  • Placebo of Pimecrolimus Cream, 1%Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects in each treatment group with treatment success (i.e., a grade of clear or almost clear; a score of 0 or 1, within the treatment area) based on the IGA of Disease Severity at the end of treatment (Visit 3; Day 15 ± 3).Time frame: Day 15

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site 4

    Hot Springs, Arkansas

  • Investigational Site 22

    Little Rock, Arkansas

  • Investigational Site 20

    Anaheim, California

  • Investigational Site 13

    Fremont, California

  • Investigational Site 26

    Norco, California

  • Investigational Site 17

    Doral, Florida

  • Investigational Site 9

    Hialeah, Florida

  • Investigational Site 16

    Miami, Florida

  • Investigational Site 18

    Miami, Florida

  • Investigational Site 19

    Miami, Florida

  • Investigational Site 25

    Miami, Florida

  • Investigational Site 8

    Miami, Florida

  • Investigational Site 12

    North Miami Beach, Florida

  • Investigational Site 3

    Ormond Beach, Florida

  • Investigational Site 7

    South Miami, Florida

  • Investigational Site 10

    Tampa, Florida

  • Investigational Site 24

    Tampa, Florida

  • Investigational Site 14

    West Palm Beach, Florida

  • Investigational Site 1

    Arlington Heights, Illinois

  • Investigational Site 21

    Lake Charles, Louisiana

  • Investigational Site 2

    Silver Spring, Maryland

  • Investigational Site 11

    Saint Joseph, Missouri

  • Investigational Site 27

    East Windsor, New Jersey

  • Investigational Site 5

    High Point, North Carolina

  • Investigational Site 23

    Raleigh, North Carolina

  • Investigational Site 15

    Cincinnati, Ohio

  • Investigational Site 6

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.